Call for Ideas: New Canadian Approaches in Radiopharmaceuticals
CQDM and CPDC (Centre for Probe Development and Commercialization) are pleased to launch a national call for ideas aimed at identifying innovative Canadian technologies, discoveries, and companies that can contribute to the next generation of radiopharmaceuticals.
Canada has developed internationally recognized expertise across the radiopharmaceutical value chain, from target discovery and isotope production to clinical development and commercialization. Through this initiative, CQDM and CPDC seek to hear about emerging Canadian innovations and connect promising teams with CPDC investment team.
What is the opportunity?
Selected applicants will be invited to present their technology, company, or research program to CPDC’s scientific experts and investment team during a virtual CQDM-CPDC Pitch Day. This call for ideas is not a grant competition and does not provide direct research funding outside investment opportunities.
CPDC has played a key role in the creation and growth of globally recognized Canadian radiopharmaceutical companies, including Fusion Pharmaceuticals and AtomVie Global Radiopharma. This Pitch Day will provide selected participants with a unique opportunity to receive feedback and explore potential investment opportunities.
In addition, CQDM will offer guidance to selected participants interested in pursuing non-dilutive funding opportunities through relevant CQDM programs, including SynergiQc and/or others.
Research Focus Areas
We welcome innovative technologies with strong scientific and commercial potential in radiopharmaceutical development, including:
- Radiotherapeutics
- Radiotheranostic pairs
- Novel radiopharmaceutical targets and targeting approaches
- Radiodiagnostics
- New applications and indications beyond oncology
- Technologies enabling radiopharmaceutical discovery, development, manufacturing, or scale-up
We are particularly interested in solutions that address important clinical needs and demonstrate a clear path toward translation and commercialization.
Who Should Apply?
Applications are welcome from:
- Canadian startups and SMEs
- Established Canadian biotechnology and pharmaceutical companies
- Researchers at Canadian universities and research institutions
- Academic-industry partnerships and multidisciplinary teams
Projects may be at various stages of development, provided they demonstrate innovation and potential commercial relevance in the radiopharmaceutical sector.
Selection Process
Submission deadline is October 15, 2026. All submissions will be reviewed jointly by CQDM and CPDC.
Please submit the completed non-confidential application pitch deck (download here) by email to Mathieu Paquette ([email protected]).
Selected applicants will be invited to participate in the CQDM-CPDC Pitch Day on December 2, 2026, where they will present their technology directly to CPDC’s investment team.
Participation in the Pitch Day does not guarantee investment or future funding. However, it provides a unique opportunity to engage directly with one of Canada’s leading organizations dedicated to the advancement and commercialization of radiopharmaceutical innovations.
About CQDM
CQDM is a non-profit biopharmaceutical research consortium whose mission is to support and facilitate multi-stakeholder collaborative R&D that accelerates translation of leading-edge discoveries into vaccines, therapeutics and diagnostics addressing unmet medical needs while generating significant benefits for the Canadian economy. For more information, consult our website www.cqdm.org and follow us on LinkedIn.
About CPDC
CPDC is a not-for-profit corporation founded in 2008, with the mission is to improve the quality of Canadian patients’ lives through the commercialization of advanced research and the clinical development of nuclear medicine. In the past 17 years, CPDC has created four Canadian commercial entities that have advanced the availability of radiopharmaceuticals to the Canadian medical community. CPDC’s business model will continue to identify and advance critical radiopharmaceuticals to meet the needs of Canadian patients and physicians through our collaborations with partners including industry, academia, and government. For more information on CPDC, visit www.cpdc.ca and follow on LinkedIn.